None listed
Conditions
Brief summary
Rapid Syllable Transition Treatment (ReST) is a speech pathology treatment which is effective for treatment of apraxia of speech in children and young people. We know it is being used clinically with adults however this has not been reported in the literature. Six adults will be provided with ReST treatment twice per week for six weeks. The research is a single-case experimental design using within participant control. Treatment will be provided by speech pathologists or supervised speech pathology students either online (zoom) or on-campus at the University of Sydney speech pathology clinic in the Susan Wakil Health Building in Camperdown NSW Australia. We hypothesise that participants speech will improve as a result of the treatment.
Interventions
12 x 1 hour sessions of Rapid Syllable Transition Treatment provided by a trained speech pathologist or a trained and supervised speech pathology student. Sessions will be twice per week for 6 weeks. Each session has a minimum dose of 100 repetitions of the treatment task.
Therapy will be provided on campus at the University of Sydney or by telehealth (patient choice).
No physical materials will be provided. No homework or adherence is required as treatment is provided in person. Treatment fidel
12 x 1 hour sessions of Rapid Syllable Transition Treatment provided by a trained speech pathologist or a trained and supervised speech pathology student. Sessions will be twice per week for 6 weeks. Each session has a minimum dose of 100 repetitions of the treatment task. Therapy will be provided on campus at the University of Sydney or by telehealth (patient choice). No physical materials will be provided. No homework or adherence is required as treatment is provided in person. Treatment fidelity will be measured by the researchers watching videos of the sessions and counting adherence to the ReST manual by the treating clinician (i.e. not patient adherence) This project is a pilot single case experimental design study to establish an effect size for a randomised controlled trial in the future. ReST uses multisyllabic nonsense words individually chosen for each participant to improve the ability to speak clearly and smoothly, transition rapidly and fluently from one sound/syllable to the next, and control of the rhythm in the form of relative emphasis, or stress, placed on each syllable within a word (McCabe et al., 2017). ReST treatment teaches patients to say the nonsense words and gets them to copy a model of someone saying the nonsense word correctly. In doing so, the person with apraxia is required to practice planning to speak, thus it is believed that the treatment addresses their apraxic difficulty directly. Details about ReST treatment and video examples of the treatment with children are available at https://rest.sydney.edu.au
Sponsors
The University of Sydney
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Diagnosis of apraxia of speech from any cause. English speaker with functional literacy in English Participants who choose to participate by telehealth will need to have their own laptop or tablet device and access to the internet
Exclusion criteria
Dementia or cognitive impairment limiting ability to individually consent. Hearing loss sufficient to prevent participation (people with hearing aids / cochlear implants who can hear speech at 30dB or lower are included). Vision loss which prevents reading of print at 20pt. Any physical disability of the head or neck which has changed the accuracy of speech production e.g. dysarthria, head and neck cancer, Any genetic or developmental diagnosis which affects speech or cognition such as Down Syndrome or Cerebral Palsy. Another serious acquired neurological disorder which affects speech or cognition such as Parkinsons disease or Alzheimers.
Outcome results
None listed